ArticleThe Journal of clinical investigation2002
Transcriptional control of viral gene therapy by cisplatin.
Article in The Journal of clinical investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Computational discovery of transcription factors associated with drug response.The pharmacogenomics journal · 2016Article
- TNF-α signaling in Fanconi anemia.Blood cells, molecules & diseases · 2014Review
- An artificially constructed radiation-responsive promoter is activated by doxorubicin.Cancer gene therapy · 2012Article
- Chapter seven--Cancer treatment with gene therapy and radiation therapy.Advances in cancer research · 2012Review
- Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression.Cancer cell international · 2011Article
- Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.International journal of oncology · 2010Article
- Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer.Cancer gene therapy · 2009Article
- Transcriptional control of Flt3 ligand targeted by fluorouracil-induced Egr-1 promoter in hematopoietic damage.Journal of biomedical science · 2009Article
- Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers.Cancer gene therapy · 2009Article
- Synergistic effect of 15-lipoxygenase 2 and radiation in killing head-and-neck cancer.Cancer gene therapy · 2008Article
- The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.Gene therapy · 2008Article
- Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy.Cancer gene therapy · 2008Article
- Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response.Clinical & experimental metastasis · 2007Article
- Ionizing radiation: a genetic switch for cancer therapy.Cancer gene therapy · 2006Review
- c-Abl regulates early growth response protein (EGR1) in response to oxidative stress.Oncogene · 2005Article
- Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin.Cancer gene therapy · 2005Article
- 5-fluorouracil and hydroxyurea enhance adenovirus-mediated transgene expression in colon and hepatocellular carcinoma cells.Journal of cancer research and clinical oncology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ionizing radiation (IR) and radical oxygen intermediates (ROIs) activate the early growth response-1 (Egr1) promoter through specific cis-acting sequences termed CArG elements. Ad.Egr.TNF.11D, a replication-deficient adenoviral vector containing CArG elements cloned upstream of the cDNA for human recombinant TNF-alpha was used to treat human esophageal adenocarcinoma and rat colon adenocarcinoma cells in culture and as xenografts in athymic nude mice. Cisplatin, a commonly used chemotherapeutic agent, causes tumor cell death by producing DNA damage and generating ROIs. The present studies demonstrate induction of TNF-alpha production in tumor cells and xenografts treated with the combination of Ad.Egr.TNF.11D and cisplatin. The results show that the Egr1 promoter is induced by cisplatin and that this induction is mediated in part through the CArG elements. These studies also demonstrate an enhanced antitumor response without an increase in toxicity following treatment with Ad.Egr.TNF.11D and cisplatin, compared with either agent alone. Chemo-inducible cancer gene therapy thus provides a means to control transgene expression while enhancing the effectiveness of commonly used chemotherapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.